Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Methods in Neurodegenerative Disease Drug Discovery -

Methods in Neurodegenerative Disease Drug Discovery

Diego Muñoz-Torrero (Herausgeber)

Buch | Hardcover
378 Seiten
2025 | 2025 ed.
Springer-Verlag New York Inc.
978-1-0716-4231-3 (ISBN)
CHF 339,95 inkl. MwSt
  • Noch nicht erschienen - erscheint am 31.01.2025
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory.

Comprehensive and thorough, Methods in Neurodegenerative Disease Drug Discovery offers practical guidance to researchers in the medicinal chemistry community.

This book explores the latest developments in the identification of biomarkers for early diagnosis of neurodegenerative diseases and methodologies for the biophysical; in vitro; cell-based; and in vivo profiling, during the early phases of drug discovery, new hits, leads, and drug candidates directed to a variety of biological targets with key pathogenic roles in neurodegenerative diseases. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory.

Comprehensive and thorough, Methods in Neurodegenerative Disease Drug Discovery offers practical guidance to researchers in the medicinal chemistry community. The methods described in this book can be readily implemented in many laboratories and will aid new and experienced researchers with creating future treatments for these devastating diseases.

Blood-Based Biomarkers for Alzheimer's Disease Diagnosis.- BACE-1 Inhibition for the Treatment of Neurodegenerative Diseases: Rationale, Assay Methodologies, and Reference Compounds.- Identification of -Synuclein Aggregation Inhibitors via High-Throughput Screening.- TDP-43 Modulation for the Treatment of Neurodegenerative Diseases: Rationale and Assay Methodologies.- Modulation of the KEAP1-NRF2 Pathway for the Treatment of Neurodegenerative Diseases: Rationale, Assay Methodologies, and Reference Compounds.- Monoamine Oxidase Inhibition for the Treatment of Neurodegenerative Diseases: Rationale, Assay Methodologies, and Reference Compounds.- Targeting Cannabinoid Receptors against Neurodegenerative Diseases: NanoLuc Binary Technology and Proximity Ligation In Situ Assay to Evaluate Pharmacological Activity of Novel Compounds and Receptors Heteromerization.- Cholinesterase Inhibition for the Treatment of Neurodegenerative Diseases: Assay Methodologies and Reference Compounds.- Use of Calcium-Sensitive Indicators for the Determination of NMDA Receptor Activity.- Cell-Based Assays to Assess Neuroprotective Activity.- Caenorhabditis elegans Models of Neurodegenerative Diseases.- A Toolkit to Model Neurodegenerative Disease in Drosophila melanogaster.- Mouse Models of Alzheimer's Disease.- Mouse Models of Amyotrophic Lateral Sclerosis.

Erscheint lt. Verlag 20.2.2025
Reihe/Serie Neuromethods
Zusatzinfo 71 Illustrations, color; 27 Illustrations, black and white; Approx. 365 p. 8 illus.
Verlagsort New York, NY
Sprache englisch
Maße 178 x 254 mm
Themenwelt Medizin / Pharmazie Pharmazie
Medizin / Pharmazie Studium
Naturwissenschaften Biologie Biochemie
Naturwissenschaften Biologie Humanbiologie
Naturwissenschaften Biologie Zoologie
Naturwissenschaften Chemie Organische Chemie
Schlagworte Alzheimer's disease • Caenorhabditis elegans models • Drosophila • Mouse Models • Parkinson's
ISBN-10 1-0716-4231-6 / 1071642316
ISBN-13 978-1-0716-4231-3 / 9781071642313
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Reinhard Matissek; Andreas Hahn

Buch (2024)
Springer Spektrum (Verlag)
CHF 109,95

von Birgit Piechulla; Hans Walter Heldt

Buch | Hardcover (2023)
Springer Spektrum (Verlag)
CHF 109,95